The Double-Edged Sword: Benefits and Risks of Combining Immune Checkpoint and Angiogenesis Inhibitors
This systematic review and meta-analysis evaluates the treatment-related adverse events of combining immune checkpoint inhibitors with angiogenesis inhibitors in advanced lung cancer. The study finds the adverse events to be ...